ANZCTR search results

The ANZCPR group is a collaborative network of perfusion and interested researchers, who share the commitment to cooperation and collaboration in the pursuit of excellence in perfusion. The ANZCPR group are uniquely positioned to promote the establishment of a unique source of information for the Cardiac Surgical (Perfusion) community, and thus to meet the following vision and mission statements. Vision: Empower all Cardiac Surgery Team Members to improve the understanding and practice of cardiopulmonary bypass to improve cardiac surgical patient outcomes. Mission: Maintain and develop the Australian and New Zealand Collaborative Perfusion Registry for cardiac surgical procedures performed throughout Australia and New Zealand. Promote the reporting and understanding of the effect of cardiopulmonary bypass on patient outcomes through encouraging evidence based practices, quality assurance, quality improvement and research. The ANZCPR group (formally known as Perfusion Downunder Collaboration (PDUC)) has evolved from the successful Perfusion Downunder (PDU) organisation which was established in 2005. The objectives of PDU were summarised in their mission statement, “to promote original prospective research into the effects of perfusion management on patient outcomes and so validate perfusion practices and interventions throughout Australia and New Zealand". This is being achieved through a meeting of scientific rigour that engages a faculty of excellence with objectives that meet those of the mission statement. The long term objective is to grow perfusionist generated research initiatives, and to seek scientific based consensus on various perfusion strategies. An overriding objective is to foster networking both scientifically and personally within the perfusion profession. The ANZCPR collaboration is an associated entity with the PDU organisation which is sponsored by Cellplex Pty Ltd. The ANZCPR collaboration is governed by a clinical steering committee independent of the sponsor.

Patients are randomised to receive 4 weeks treatments with a 25g whey protein 'preload' taken 30 min before each of the 3 main meals daily for 4 weeks, or placebo. After a 2 week 'washout' period, they cross over to the alternate treatment. They will attend the hospital for a test meal of radiolabelled mashed potato at the beginning and end of each intervention period, to evaluate whether the capacity of the protein preload to lower blood glucose concentrations and slow gastric emptying after the meal are sustained over 4 weeks.

This study aims to test the effectiveness of a patient led goal setting intervention in the treatment of chronic low back pain.

The aim of the trial is to examine the hypothesis that dietary interventions, which slow gastric emptying and/or the rate of carbohydrate absorption, will be associated with a corresponding reduction in the decline in endothelial dysfunction that is observed after meals. Subjects will be studied on 3 occasions in random order, after an overnight fast. They will consume a 13C-octanoic acid labelled mashed potato meal ('meal 1'), or the same meal mixed with 9 g guar ('meal 2') within 10 min, or 'meal 1' divided into 12 equal portions over 60 min ('meal 3'). Brachial artery flow mediated dilatation will be measured every 30 min for 120 min, breath samples will be collected to evaluate gastric emptying, and blood will be sampled to measure blood glucose and serum insulin.

This study is a randomised, double-blind, placebo-controlled, crossover trial. A total of 34 healthy right-handed male and female participants aged 18 to 40 years old will take part in the study. Participants will be required to attend three sessions. The first visit is a screening and practice session, assessing eligibility and familiarising participants with cognitive tasks. Finally, structural brain information will be obtained during an MRI scan. Subsequently, two testing days will be conducted a minimum of 48 hours apart. Participants will be assigned to a treatment sequence, such that one of each treatment is received across the two testing days. At testing days participants will receive a standardised lunch upon arrival, followed by a 30-minute break, then undergo baseline assessment of stress, mood, and cognitive function. After baseline assessment, treatment will be administered. 30-minutes after administration of treatment, participants will once again undergo assessment of stress, mood, and cognitive function, followed by recording of brain activity during rest and an attention task using magnetoencephalography (MEG). After this, the assessment of stress, mood, and cognitive function will be conducted a third time. Participants will consume all interventions orally as a drink of approximately 430 ml (14.5 fl oz). Both active and vehicle control treatments contain identical ingredients of sweeteners (crystalline fructose and sucralose) and preservatives (sodium benzoate, potassium sorbate) , gum acacia and malic acid. In addition, the active treatment contains L-Theanine (200 mg, L-Tea-Active), L-Alpha Glycerylphosphorylcholine (Alpha GPC; 25 mg)), phosphatidylserine (1mg) and chamomile (10 mg).

The purpose of this study is to investigate the effectiveness of an 8- week internet-delivered cognitive behaviour therapy (iCBT) as a preventative intervention for depression in older adults with two or more chronic diseases. It is hypothesised that, on the primary outcomes of depressive symptoms and rate of depressive disorders, the iCBT group will have fewer depressive symptoms or diagnoses of depression at post-treatment and follow-up than the control group who receives no intervention.

: This PhD study is an observational cohort study of fluid resuscitation in children with severe sepsis. The primary aim is to determine the effect (both in size and duration) of fluid bolus therapy on stroke volume in children with severe sepsis. Secondary aims include: the ability if IVC ultrasound to predict fluid responsiveness; the ability of lung ultrasound to detect early harms from fluid bolus administration; and the correlation between fluid bolus administration and changes in vital signs.

Traumatic events, such as serious injury, interpersonal assault or natural disaster have a high lifetime incidence. In the aftermath of such an event, individuals may develop emotional disorders (e.g., posttraumatic stress disorder, Anxiety Disorders or Depressive disorders). Many trauma survivors develop multiple emotional disorders and can therefore present for treatment with complex difficulties. This demands psychological interventions that are flexible and applicable across disorder types. Such approaches, termed 'transdiagnostic treatments', have been developed for use across emotional disorders. The aim of this project is to conduct the first randomised controlled trial testing the efficacy of the early delivery of a psychological treatment known as the 'Unified Protocol for Transdiagnostic Treatment of Emotional Disorders' in (i) reducing the prevalence and severity of emotional disorders and (ii) lowering disability and raising quality of life in a sample of severe injury survivors. Based on our earlier work, a two stepped screening process will identify patients eligible for the treatment component of the study. The first step is to screen 1650 injury patients for ‘risk’ of developing an emotional disorder during their acute hospitalisation stage using the Posttrauma Adjustment Screen. The second step is to reassess patients identified as ‘ at risk’ (n= 900) four weeks after injury to assess for emotional disorders meeting diagnostic criteria using the Mini International Neuropsychiatric Interview. Of these, we expect the sample will comprise 115 participants who meet diagnostic threshold for at least one anxiety disorder, major depressive disorder or PTSD four weeks after they have sustained a traumatic injury and who take up the offer of treatment. These participants will be randomly allocated to either an (a) Treatment (Unified Protocol early intervention/UPEI) or (b) Control (usual care – UC) group. The treatment condition will consist of 10-14 weekly therapy sessions using the 'Unified Protocol for Transdiagnostic Treatment of Emotional Disorders' with a trained clinician. Participants will be assessed using self report questionnaires to determine types of emotional disorders and severity of symptoms at: (a) pre treatment, (b) mid treatment, (c) post treatment and (d) six months follow up. Quality of life, disability, perceived control and problematic emotion regulation strategies will also be measured at all three time points.

The purpose of this study is to look at the effects of a resiliency and well-being program (Boomerang Effect program), that is being taught to high schools students. The study also looks at the effects of the different skills that are taught such as positivity, motivation, mindfulness, emotional management and other resiliency skills. We expect that the students who are taught the skills will show improvements in their resiliency, well-being and a range of coping skills.

This study will assess the safety of using hypofractionated radiotherapy concurrent with carboplatin and paclitaxel chemotherapy regimen for the palliative management of esophageal cancers. Who is it for? You may be eligible to join this study if you are aged 18 years or above, have been diagnosed with esophageal cancer for which curative surgery or radical chemoradiotherapy is not appropriate, and are experiencing symptoms of dysphagia (difficulty swallowing). Study details The first three participants in this study will undergo a total of 15 sessions of hypofractionated radiotherapy together with weekly intravenous injections (into the veins) of the chemotherapy drugs Carboplatin and Paclitaxel. If the initial regimen is tolerated in the participants, the radiotherapy dose given per session will be increased in subsequent groups (resulting in smaller total number of sessions). Participants will be monitored for safety throughout the treatment. They will also be followed for up to 1 year in order to evaluate treatment effect on dysphagia,quality of life and survival time.